R 1065

Drug Profile

R 1065

Alternative Names: VMR 003; VR 1065

Latest Information Update: 01 Aug 2002

Price : $50

At a glance

  • Originator Roche; Vernalis Group
  • Class Obesity therapies
  • Mechanism of Action G protein-coupled receptor modulators; Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 01 Aug 2002 Discontinued - Phase-I for Obesity in United Kingdom (unspecified route)
  • 29 May 2002 Phase-I clinical trials in Obesity in United Kingdom (unspecified route)
  • 22 May 2002 Preclinical trials in Obesity in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top